Rationale: Sustains CD8+ T cell glycolysis in glucose-deprived TME; Clinical: Phase II (NCT05809336) shows 50% disease control; Delivery: Enteric-coated PLGA microspheres reduce renal clearance. Challenge: Biphasic A2aR signaling suppresses Th1 responses in IFN-γ-deficient TME; hyperuricemia in 15% gout patients. This evidence concerns the gene CD8A and gout.